A little less than 6 months after managing to gather a massive $51 million in a Series A project that was led by OrbiMed which also included the Novartis Venture Fund, the Adicet Bio was able to secure a 5-year agreement with $REGN (Regeneron Pharmaceuticals). An amount of $25 million will be paid up front by the Biopharma to do research and develop many clinical applicants for the different solid tumor and hematological cancers
In discussions with the FierceBiotech, Dr. Micheal Aberman advised that they are prepared to go anywhere science takes them which may often mean that they will explore as many approaches as possible. Dr. Aberman is the Investor Relations and Regeneron SVP of Strategy. He also mentioned that this would be true for immuno-oncology in which scientists see great potential in mechanisms and technologies available today such as bispecific antibodies, checkpoint inhibitors, and CAR-Ts - immune cell products.
He also added that scientists had made a number of research associations within the areas that make up the core Veloci-technologies. It’s too early to see whether they have any promising offers as there are many unique and different applications for each as well as the benefits combination therapies.
The plan by the partners is to develop CARs which is human chimeric antigen receptors and TCRS which is T-cell receptors that will focus on disease-specific cell surfaces by creating antigens that kill tumor cells. Regeneron has the options to the commercial right and development rights for an unnamed number of candidates, under the deal.
The Contributions of Adicet
Adicet has the option to either contribute to the development and the commercialization or as it stands rather bring in undetermined royalty payments. Regeneron is also able to use the targeting molecules that developed a part of the contract in its bispecific and monoclonal antibody programs which also include those partnered with ($SNY) Sanofi.
Adicet and Regeneron have a plan to make cell-based contenders that are ready to sell. This will not be similar to the current process of creating autologous that is based on an individual patient’s own cells. The hope is that Adicet’s foundation will be useful in dealing particularly with solid tumors which engineered cellular therapies are still in the pipeline to be demonstrated. The treatments of blood cancers such as lymphoma or leukemia have already shown promise with them, though.
Adicet is also developing a novel approach for an immune off the shelf therapy that is aimed at overpowering any other challenges that are associated with the current approaches that include efficacy in the solid tumors. The properties of cell products will allow them to penetrate better into these solid tumors while functioning within the tumor microenvironment.
Adicet who is the President and CEO of Aya Jakobovits advised that Regeneron’s leading-edge platform of technologies and capabilities allow the engineering of the human immune system cell together with the novel disease specific fully TCR and CAR-T targeting moieties to improve the cell safety and efficacy.
The Menlo Park, around the time of Series A financing, they also acquired an Israeli Company called Applied Immune Technologies that will develop immunotherapies to work with the intracellular proteome.